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Abstract
Recent studies have proposed an association between hyperlipidemia and venous thromboembolism
(VTE) We review the epidemiological evidence Imking dyslipidemia with VTE and examine several
possible underlying mechanisms We discuss the possible role of HMG CoA reductase mhibitors
(statins) m the prevention and treatment of VTE and suggest future directions for research
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Any textbook of cardiovascular medicme published withm
the past 20 years is sure to contam a lengthy discussion of
the role of dyslipidemia m the development of both athero-
sclerosis and acute artenal thrombosis [1]. Elevated total
serum cholesterol, elevated low-density-lipoprotem choles-
terol (LDL-C), and decreased high-density-lipoprotein cho-
lesterol (HDL-C) are all well-estabhshed nsk factors for
coronary heart disease [1], while there is still debate about
the contribution of hypertriglycendemia to this process [2].
Perhaps it is not surprising that major textbooks of hema-
tology [3] and thrombosis medicme [4] do not mention
any role for dyslipidemia m the pathogenesis of venous
thromboembolism (VTE) One reason may be the absence
of pathological evidence of hpid deposition withm either
the venous System or the so-called 'red thrombus' that
may develop therem [5]. Accordingly, there has been little
hypothesis-generatmg research explonng the mterplay
between hpid dysfunction and VTE In the followmg paper,
we discuss the evidence Imking hyperlipidemia to the for-
mation of VTE and the possible role of HMG CoA reduc-
tase mhibitors (statins) in its prevention and treatment
What is the epidemiological evidence linking
dyslipidemia to VTE?
Two cohort [6,7] and six case-control studies [8-13]
have exammed the relation between dyslipidemia or serum
hpoprotem (a) [Lp(a)] and VTE Goldhaber et al retrospec-
tiveiy evaluated several nsk factors among 46 adults diag-
nosed with pulmonary embohsm at autopsy and 3424
individuals enrolled at baselme in the Frammgham Study
[6]. Total serum cholesterol was observed to be a signifi-
cant risk factor for pulmonary embolism m women
(P = 0.049), but not men (P> 0 05). In the Nurses' Health
Study, 280 middle-aged women with a self-reported
history of pulmonary embohsm were compared with a
cohort of 112,542 women without a history of pulmonary
embolism [7] (Table 1), They found that those with a self-
reported diagnosis of hypercholesterolemia were at no
increased nsk for pulmonary embohsm (multivanate rela-
tive risk 1.1, 95% confidence mterval [Cl] 0.7-1 5).
Kawasaki ei al were the first to demonstrate an associa-
tion between hypercholesterolemia and objectively venfied
deep vem thrombosis (DVT) of the leg among middle-aged
ASA = acetylsahcyhc acid, CABG = coronary artery bypass graft, Cl = confidence mterval, DVT = deep vem thrombosis, FVII C = factor VII coagu
lant, HOL C = high density-hpoprotem cholesterol, HERS = Heart Estrogen Replacement Study, HMG CoA = 3-hydroxy-3-methylglutaryl coenzyme
A, HR = hazard ratio, LDL C = Iow density-lipoprotem cholesterol, Lp (a) = hpoprotem (a), OR = odds ratio, VTE = venous thromboembolism 165
Current Controlled Trials in Cardiovascular Mediane August 2001 Vol 2 No 4 Ray and Rosendaal
Table 1
Epidemiological studies of the associated risk between dyslipidemia and venous thromboembolism (VTE)
Study [referenoe]
Goldhaber ei a/ [7]
Kawasaki ef al [8]
Nowak Gottl ei al [1 0]
von Depka et al [1 1]
Mean age








% cases risk factor ratio
VTE with situational among (95% Cl)










TC> 5 7 mmol/L and TG > 1 7 mmol/L
TC> 5 7 mmol/L and TG < 1 7 mmol/L
Lp(a) > 30 mg/dL
Lp(a) > 1 0 mg/dL
Lp(a) > 20 mg/dL








1 1 β 7-1 5)
5 1 (20-130)
2 6 (1 2-5 3)
7 2 (37-145)
1 6 (1 2-2 2)
2 2 (1 5-3 3)
3 2 (1 9-5 3)
*Defmed äs either immobilization (l e trauma, surgery, or bedridden) or presence of an indwelling venous catheter at the Site of thrombosis DVT =
deep vein thrombosis, Lp(a) = lipoprotein (a), PE = pulmonary embohsm, TC = total cholesterol, TG = tnglycerides, VTE = venous
thromboembolism
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men and women [8]. In companson with matched con-
trols, the risk for DVT was greatest in the presence of ele-
vated fastmg total serum cholesterol, either with or without
concomitant hypertnglycendemia (Table 1). Among mdi-
viduals whose total serum cholesterol was below
5.8 mmol/L, isolated hypertnglycendemia was not a risk
factor for DVT (odds ratio [OR] 0.9, 95% Cl 0 4-2.1).
McColl and colleagues compared 62 women with objec-
tively confirmed VTE before age 50 years with 98 healthy,
age-matched controls and observed a Iower mean fastmg
total serum cholesterol among cases versus controls
(4.74 versus 5.13 mmol/L, respectively, P<0.02) [9].
Although the mean LDL-C was also Iower among the
cases (2.76 versus 3.18 mmol/L, respectively; P = 0.01),
serum tnglycerides were slightly higher (1.29 versus
1.09 mmol/L, respectively; P = 0.02), and there was no
difference seen for serum Lp(a) (P = 0.47).
Two subsequent studies, both of similar design, evaluated
the risk for VTE in the presence of elevated serum Lp(a) in
children [10] and adults [11] (Table 1). In the pediatric
study, an Lp(a) concentration at or above the upper-
quartile value of 30 mg/dL was significantly associated
with VTE, m companson with the Iowest-quartile value. This
effect persisted among a subgroup of children without an
underlymg illness (adjusted OR 7.1, 95% Cl 2.7-18.6)
[10]. In the study among adults, an Lp(a) concentration
greater than 30 mg/dL was also associated with VTE [11],
even after adjustment for the presence of other common
thrombophilia risk factors (adjusted OR 2.8, 95% Cl
1.6-4.9) [11]. Furthermore, the risk for VTE m that study
rose hnearly with mcreasmg Lp(a) concentrations (Table 1).
In a seventh study, Lp(a) concentrations were measured m
64 patients with previous VTE and 64 matched controls
with either atrial fibnllation or valvular heart disease [12].
The median Lp(a) concentrations were not significantly dif-
ferent between cases and controls (69 versus 83 mg/L,
respectively; P = 0.34). An eighth group of mvestigators
compared plasma Lp(a) concentrations m 40 patients with
chronic thromboembolic pulmonary hypertension, 50
patients with pnmary pulmonary hypertension, and 50
matched disease-free controls [13]. In that study, median
Lp(a) concentrations were higher m subjects with chronic
thromboembolism (26.7 mg/dL) than m those with either
pnmary pulmonary hypertension (9.7 mg/dL) or no disease
(70 mg/dL) [13],
Although some studies suggest an association between
hyperlipidemia and VTE, their results conflict somewhat. The
degree of precision and moderately high effect size seen m
the three positive studies (Table 1), considered in conjunc-
tion with a 20% or greater prevalence of dyslipidemia
among the cases, suggests that elevated concentrations of
total serum cholesterol and Lp(a) may be important risk
factors for VTE m adults and children. While some studies
used fastmg samples, only two described collectmg speci-
mens at least 3 months after the initial thrombotic event
[10,11]. Specimen collection remote from the initial VTE
event may be important, smce lipids are known to declme in
the presence of acute vascular events, such äs VTE or
myocardial infarction [14,15], potentially mtroducing a nega-
tive confoundmg effect between dyslipidemia and VTE. In
the two negative cohort studies, their methods for lipid mea-
surement were not reported [6,7], while m the Nurses'
Health Study, recognition of pulmonary embolism and
hypercholesterolemia depended on a self-reported diagno-
sis of both diseases [7], thereby castmg some doubt on the
validity of their fmdmgs. Future studies could help to clarify
whether dyslipidemia is a causal risk factor for VTE and, if
so, which lipid molecule is most thrombogenic.
Current Controlled Trials in Cardiovascular Mediane August 2001 Vol 2 No 4 Ray and Rosendaal
coronary Artery Bypass Graft (Post-CABG) tnal [50].
Among patients randomized to receive high-dose lovas-
tatin (40 mg daily), there was a sigmficant reduction in
both the rate of progression of saphenous vein graft
occlusion and the need for coronary revasculanzation, m
companson with patients given Iow-dose lovastatin
(2.5 mg daily) [51]. Interestingly, lovastatin had no effect
on Lp(a) concentrations, but lipoprotem B concentra-
tions were significantly reduced m the high-dose group
[52], In a more recent clmical tnal, patients with preoper-
ative hypercholesterolemia (total serum cholesterol
greater than 6 2 mmol/L) were randomized to receive
either no therapy (Group 1, n = 37) or 4 weeks of preop-
erative simvastatin, 20 mg daily (Group 2, n = 40). Those
assigned simvastatin contmued their therapy for 1 year
postoperatively. Nmety-eight percent of participants
underwent routme follow-up angiography at 1 year. The
rate of detectable graft disease at 1 year, the primary
study endpomt, was 46% m Group 1 and 10% m
Group 2, mdicating a benefit with statm therapy (relative
nsk 0.30, 95% Cl 013-0.66). The rate of myocardial
mfarction was also significantly higher in Group 1 (5%)
than m Group 2 (0%) (P = 0.036). The greatest relative
benefit with statm therapy was observed among those
with saphenous vem grafts [53].
Perhaps the most compellmg direct evidence that statms
may reduce the nsk for VTE comes from two recent
studies [54,55]. In the Heart Estrogen Replacement Study
(HERS), 1380 women were randomized to hormone
replacement therapy and 1383 women to placebo [54].
Durmg 10,985 woman-years of follow-up, 47 women
developed VTE. In a post-tnal analysis, it was found that
statms, but not other lipid-lowermg agents, reduced the
nsk for VTE by 50% (adjusted hazard ratio [HR] 0.5, 95%
Cl 0.2-0.9). The association between statm use and DVT
was also evaluated, m a retrospective Canadian cohort
study comprismg 125,862 men and women aged
65years and older [55] After 190,601 person-years of
observed drug use, there was an associated decreased
nsk of DVT among statm users compared with controls
prescnbed thyroid replacement hormones, even after con-
trollmg for the presence of cancer, recent hospitahzations,
and ASA or warfarm use (adjusted HR 0.78, 95% Cl
0.69-0 87). Just äs m the HERS study, nonstatin lipid-
lowermg agents did not appear protective agamst DVT
(adjusted HR 0.97, 95% Cl 0.79-1.18). In both studies,
however, the apparent protective effect of statms agamst
VTE might also be explamed by the possibility that statm
users were healthier (i.e healthy-user bias) or had fewer
VTE nsk factors that were not measured.
What further evidence is needed for clinicians?
Dyslipidemia and VTE
We argue that, at present, dyslipidemia should not be
168 mcluded äs part of any thrombophilia work-up m persons
with idiopathic VTE Consistent epidemiological evidence
is needed to demonstrate that commonly assayed hpids
(e.g. total serum cholesterol, LDL-C, triglycerides), äs well
äs other hpoprotems [e.g. Lp(a), lipoprotem B], are risk
factors for VTE. In such studies, mvestigators should con-
sider collectmg fastmg specimens remote from the time of
the VTE event. Investigators m previous and future epi-
demiological studies and clmical trials designed to evalu-
ate the effect of hpid reduction on cardiovasculaj disease
might also consider evaluatmg data on VTE events among
their study participants.
Statins and VTE
Statms cannot be recommended for use m either the pre-
vention or the treatment of VTE. Research studies should
attempt to quantify the risk reduction for VTE with statm
use. A clmical tnal aimed at secondary prevention of
recurrent VTE may be one startmg pomt. For example,
patients who have had a first idiopathic VTE and who
have completed 3 or 6 months of anticoagulant therapy
could be randomized to either contmue warfarm for
another 12 to 18 months [56] or discontmue their war-
farm and begm on statm therapy The primary, composite
endpomt of such a tnal might be the development of
recurrent VTE or major hemorrhage. Before such a tnal
can be justified, more epidemiological evidence is
needed Imkmg statm use to reduced VTE.
A greater understandmg is also needed about whether
there is a difference m the antithrombotic properties of
the vanous statm agents, either m conjunction with, or
mdependent of, their lipid-lowermg properties. For
example, m an audit of 1 26 mdividuals with atheroslcero-
sis who switched from simvastatin (mean daily dose
22 mg) to fluvastatm (mean daily dose 37 mg), there was
a sigmficant nse in total serum cholesterol, LDL-C, and
triglycerides, äs well äs an mcrease m the subsequent
number of artenal thrombotic events after a mean of 1 7
weeks [57]. In addition, researchers should focus on
whether statms, m conjunction with drugs such äs ASA
[58], may offer an alternative and safe approach to VTE
prevention among mdividuals at high nsk for anti-
coagulant-related hemorrhage.
Conclusion
In summary, there is a new and growmg body of epi-
demiological evidence supportmg a possible link
between dyslipidemia and the development of VTE, äs
well äs the potential for statms to reduce the nsk of
VTE. The association between both elevated total serum
cholesterol and Lp(a) and VTE is not consistent,
although studies have shown that dyslipidemia is a sig-
nificant nsk factor for CABG vem graft occlusion, and
that statms reduce that risk. Fmally, prelimmary research
suggests that statms may Iower the risk for VTE through
several mechanisms.
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